Marie-Pier St-Laurent, MD, FRCSC, explains how NeoBLAST combines imaging, TURBT, and ctDNA to identify candidates for bladder-sparing surveillance.
Commentary|Articles|July 21, 2026
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
Author(s)Tyler Garman, MD
Fact checked by: Hannah Clarke, Cheney Gazzam Baltz
Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG-naive NMIBC.
Advertisement
Advertisement
As ongoing BCG shortages continue to challenge the management of high-risk non–muscle-invasive bladder cancer (NMIBC), interest has grown in alternative first-line intravesical treatment strategies. Updated findings from the phase 2 GEMDCE trial (NCT04386746) of first-line intravesical gemcitabine and docetaxel (gem/doce) showed durable 3-year high-grade recurrence-free survival, no progression during treatment, and a manageable safety profile in patients with BCG-naive high-risk NMIBC.1
Related to this article
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement